BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced solid third quarter 2008 financial results. For the three months ended September 30, 2008, Enzon reported a net loss of $2.0 million or $0.05 on a diluted per-share basis, as compared to a net income of $87.5 million or $1.23 on a diluted per-share basis for the third quarter of 2007. In 2007, the third quarter results were impacted by the $88.7 million net gain from the sale of a portion of our PEG-INTRON royalty asset.
